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Abstract
Background: Factors associated with the survival of truth of clinical conclusions in the medical literature are unknown. We
hypothesized that publications with a first author having a higher Hirsch’ index value (h-I), which quantifies and predicts an
individual’s scientific research output, should have a longer half-life.
Methods and Results: 474 original articles concerning cirrhosis or hepatitis published from 1945 to 1999 were selected. The
survivals of the main conclusions were updated in 2009. The truth survival was assessed by time-dependent methods (Kaplan
Meier method and Cox). A conclusion was considered to be true, obsolete or false when three or more observers out of the six
stated it to be so. 284 out of 474 conclusions (60%) were still considered true, 90 (19%) were considered obsolete and 100
(21%) false. The median of the h-I was=24 (range 1–85). Authors with true conclusions had significantly higher h-I
(median=28) than those with obsolete (h-I=19; P=0.002) or false conclusions (h-I=19; P=0.01). The factors associated
(P,0.0001) with h-I were: scientific life (h-I=33 for.30 years vs. 16 for,30 years), -methodological quality score (h-I=36 for
high vs. 20 for low scores), and -positive predictive value combining power, ratio of true to not-true relationships and bias (h-
I=33 for high vs. 20 for low values). In multivariate analysis, the risk ratio of h-I was 1.003 (95%CI, 0.994–1.011), and was not
significant(P=0.56).Inasubgrouprestrictedto111articleswithanegativeconclusion,weobservedasignificantindependent
prognostic value of h-I (risk ratio=1.033; 95%CI, 1.008–1.059; P=0.009). Using an extrapolation of h-I at the time of article
publication there was a significant and independent prognostic value of baseline h-I (risk ratio=0.027; P=0.0001).
Conclusions: The present study failed to clearly demonstrate that the h-index of authors was a prognostic factor for truth
survival. However the h-index was associated with true conclusions, methodological quality of trials and positive predictive
values.
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Introduction
Science progresses via a series of paradigms that are held to be
true until they are replaced by a better approximation of reality
[1]. In surgery and medicine two studies have estimated that the
half-life of truth for clinical conclusions in the literature is 45 years
[2,3]. We had tried to identify factors that were independently
associated with this truth survival, and found only two, one
expected (the negative conclusion of the publication) and one non-
expected (the absence of meta-analysis in the methodology used)
[3]. We therefore concluded that better prognostic factors should
be found to better convince clinicians of the long term utility of
evidence-based medicine [3,4].
In the previous study, we did not analyze any author’s related
factor [3]. In the present study we hypothesized that publications
with a first author having higher h-I which quantifies [5] and
predicts an individual’s scientific research output [6,7], should
have longer survival. An association between the h-I and truth
survival could be also the proof of concept of using this type of
method for validating such indexes. So far, the h-I has been
validated using ’‘‘scientific achievement’’, as defined by criteria
which are finally very redundant: the number of citations [6], -
peer review [8], -grant proposals [9] or quantitative performance
measurements [10-11].
We used 474 previously assessed articles [3] with an identified
first author, and in which the survival of the main conclusions were
updated in 2009.
Methods
Summary of the initial study methodology [3]
Selection of articles. We identified original articles concern-
ing cirrhosis or hepatitis in adults from 1945 to 1999 in 11 five
year periods. The articles selection was stratified into 3 categories:
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year period we selected 20 non-randomized articles from two
journals, 10 published in Lancet and 10 in Gastroenterology. In
each period we tried to select 20 randomized trials on cirrhosis or
hepatitis, 10 from Lancet and 10 from Gastroenterology. We
chose these two journals because they have published clinical
studies in hepatitis and cirrhosis since at least 1945, because they
are peer- reviewed with a high level of selection and have a high
impact factors greater than 10. A hand search was utilized to select
articles from 1945 to 1985. As a true randomization was very
difficult to organize we used a selection by order of publication
inside each 5 year period. The first article of the period concerning
cirrhosis or hepatitis was chosen, then the last of the period, then
the second, and then the one before the last and so on up to 20
articles. From 1985 to 1999 we used PUBMED electronic search
specifying the following ‘‘limits’’: cirrhosis or hepatitis, human,
Lancet or Gastroenterology. Abstracts were randomly downloaded
using a similar selection method, stratified by five year periods. We
selected the first abstract listed on the first electronic page, then the
first on the last electronic page, then the last on the second
electronic page, then the last on the page before the last and so on
up to 20 articles.
In each period we tried to select 20 randomized trials on
cirrhosis or hepatitis, 10 from Lancet and 10 from Gastroenter-
ology. This was possible from 1970 to 1999. In the periods from
1945 to 1969 we selected all identified randomized trials whatever
the journal, with a range from four (1945-1950) to 20 trials (1965-
1969). From 1945 to 1982 we used the_ manual method the hand
searching method as previously described [5]. From 1982 to 1985
we completed the random selection by hand searching and from
1985 to 1999 by PUBMED as described for non-randomized
studies.For the meta-analyses, we used a hand searching method
as described in the systematic review of meta-analyses [12]. To be
included, meta-analysis should be based on trials in the field of
hepatology and published as full papers before 2000. The
following operational definition of meta-analysis was adopted: a
study in which a computation of an overall treatment effect, based
on the estimation of treatment effect in each trial, was performed,
and reported with its 95% con- fidence interval or with the
corresponding statistical test. Meta-analyses on childhood diseases
were not included [12].
Selection of conclusion. The one conclusion from each
abstract that seemed to best summarize the findings was copied to
a database. Editing of these sentences was restricted to the
rephrasing of outdated terminology and the elimination of
redundant words.
Observers. Six hepatologists, called the observers, assessed
the form which contained the selected conclusions in a random
order. The observers were fulltime hepatologists from different
subspecialties but working in a hospital and aged from 31 to 65
years. Observers were blind to the period, the journal, the authors,
the method (meta-analysis, randomized, non randomized), and the
methodological quality from which each conclusion was derived.
They classified each conclusion into one of three categories: 1) still
true in 2000 (updated in 2009), 2) obsolete but not false, 3) false.
Prognostic factors. The following seven factors were
analyzed; 1) the design (meta-analysis, randomized trial, not
randomized study); 2) the quality assessment of randomized trials
and meta-analyses had been made independent of this study by one
of us (TP) by means of scoring methods [13-15]; articles were rated
as high quality when the score was greater or equal to the mean (12
for randomized trials, 27 for meta-analyses) and as low quality when
lowerthan the mean.Non-randomized studies wereclassifiedaslow
methodological quality as there is no specific scoring method; 3)
negative or positive conclusions; 4) the type of disease (hepatitis,
portal hypertension, other); 5) the domain of clinical research
(therapeutic, diagnostic or other study; other studies were defined as
explanatory studies not assessing treatment or diagnostic tests); 6)
the journal of publication (Lancet, Gastroenterology, other); and 7)
the specialty (medicine or surgery).
Statistical analysis. A conclusion was considered to be true,
obsolete or false when three or more observers out of the six stated it
to be so. When there was a split decision 3 to 3 regarding conclusions
being true-not true the final conclusion was considered to be true;
these splits concerned 9 out of 474 (1.9%) articles. When there was a
splitdecision3to3regardingconclusionsbeingobsolete-nonobsolete
thefinal conclusion wasobsolete; these splitsconcerned 26 articles out
of 474 (5.5%). When the article was not classified as either true or
obsolete it was considered as false. The half-life was calculated
according to the Kaplan Meier method using the censored timeas the
duration between the year of publication to the year 2000 (updated in
2009). The censored time is the time at risk of being refuted or found
to be obsolete. We analyzed the truth survival: if the conclusion was
assessed to be still true the case was censored at the end of follow-up.
If the conclusion was assessed to be false or obsolete it was considered
as a failure. The comparison between factors used the two-sided
logrank test and the multivariate analysis proportional hazard
regression analysis.
Hirsh index
The h-I of first authors was the main prognostic factor assessed
in the present study. The h-I were assessed in the first 6 months of
2010. The h-I was originally computed using Google Scholar
(‘‘Google Scholar Universal Gadget’’) for first authors. Because
Google Scholar is not a perfect Gold Standard of estimating h-I,
other methods were used. The commonness of last names can
introduce a false estimate of the h-I [16] and therefore for the high
risk names we used ‘‘liver’’ as a supplementary selection criteria in
the Scholar research. As the Scholar research should be less
performing for the oldest publications, the h-I was also assessed
using the Scopus database for first authors of articles that were
published after 1995,and using the ISI data-base. Only the authors
still publishing after 1980 have been taken into account as the
applicability of ISI search was very low in the older periods.
The date of the publication as well as the scientific age of the
author (time between first and last publications) are mathemati-
cally associated with the h-I, which is cumulative, and increases
over time [5,8,10,16-17]. Therefore analyses were stratified
according to the publication date (1945-1964, 1965-1979, 1980-
1999), the rate of the h-I (h-I/scientific life in years) was estimated
and the scientific life duration of the author was included in
multivariate analyses.
The seven characteristics of studies [3] and two author
characteristics associated with the h-I in the literature (gender of
author, and place of residence) [10,16-17] were analyzed as
possible confounding factors in the prognostic analyses. The
gender was unknown from the Scholar research and from the first
name initials. We used the personal knowledge of coauthors and
the details of first name given by Scopus.
Updated methods
No change was made for the selection of articles, and
methodological quality assessment. Observer conclusions were
updated in 2009, that is with 10 years more of follow-up. One
previous observer had retired, two had moved and two new ones
agreed to participate (MM, DT). The observers were asked to
modify their previous conclusions if necessary. A conclusion was
changed when at least three observers out of the five stated it to be
Truth Survival
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previously obsolete became true, two previously true became false
and one became obsolete.
The main a priori endpoint was the prognostic value of the h-I
(quantitative value) in the multivariate analysis including previ-
ously identified prognostic factors. The other ‘‘significant’’ P values
were detailed when ,=0.10 and were described as NS if .0.10.
Statistical descriptions and analyses used non-parametric
methods. Median was expressed with a 95% confidence interval.
Multiple comparisons used the Kruskal Wallis variance analysis
with Dunn s’ multiple comparison test. In comparison with the
previous analysis the same time-dependent analyses were used. [3]
A modification was made for the estimated time of censoring for
obsolete or false conclusion, according to a pertinent critique [18].
Very old publications that had been declared obsolete at the end of
follow-up could cause the duration of survival to be overestimated
if they were in fact been obsolete or false many years earlier.
Therefore for each obsolete or false conclusion, we estimated the
year in which it became obsolete or false. We added the duration
of scientific life in the Cox proportional regression model as a
covariate for adjusting the prognostic value of the h-I. The
conclusions of the first analysis and the factors associated or not
associated with truth survival did not change [19].
It was not possible to assess directly the h-I of the author at
the time of publication (baseline h-I) for each article included
in the present survey. However it was possible to estimate the
baseline h-I using backwards the progression rate of the given
h-I. For example a Scholar h-I=81 in 2010 (h-I2010), for an
author with a mean speed (h-speed) of 2.53, it was possible to
extrapolate that for one article of the present database
published in 1995 (h-Ibaseline) the h-I was at this baseline date:
h-Ibaseline=h-I 2010- (h-speed 6 (2010-1995)) =81-2.53x(15)=
43. This baseline h-I was also assessed in the prognostic
analysis.
It has been suggested that for a special ‘‘outstanding category’’
of top-scientists, citation’ indexes can reflect scientific ‘‘quality’’
[20]. Therefore we planned an analysis of ‘‘top-hepatologists’’
conclusions, using the cutoff which select the 30 highest h-I. Using
h-Scholar the cutoff was h-I =60; this resulted in 33 articles
(6.1%), as there was 4 ties at h-I =60. Using h-Scopus the h-I
cutoff was 33 and for ISI 38.
We have not previously observed a prognostic value of studies
according to criteria based on methodological quality scoring
systems [3]. Recently Ioannidis proposed a classification of
research findings in 9 classes of positive predictive values according
to various combinations of power, ratio of true to not-true
Table 1. Hirsch index and characteristics of included first author.
Characteristics Publication year
1945-1964 1965-1979 1980-1999 Total
Total selected 110 120 244 474
Hirsch Index
Scholar 2010 13 (9-15) 23 (17-28) 30 (26-33) 24 (20-27)
Scholar baseline 0 (0-0) 1 (0-4) 6 (5-8) 3 (1-4)
Scopus* NA NA 16 (15-17) NA
ISI** 8 (3-11) 11 (10-14) 21 (17-25) 17 (15-18)
Google Scholar/yr 0.76 (0.65-0.89) 0.70 (0.57-0.83) 1.08 (0.96-1.14) 0.87 (0.82-0.93)
Scopus/yr* NA NA 1.03 (1.00-1.14) NA
ISI/yr** 0.19 (0.08-0.50) 0.32 (0.24-0.41) 0.72 (0.63-0.88) 0.58 (0.45-0.63)
Residence
US 72 52 49 173
UK 20 22 31 73
Italy 1 3 49 53
France 0 5 31 36
Europe (other) 7 19 51 77
Asia 4 9 21 34
Other 6 10 12 28
Gender
Male 106 111 212 429
Female 4 9 32 45
Scientific life
First publication 1956 (1952-1957) 1968 (1967-1970) 1979 (1977-1980) 1970 (1967-1971)
Last publication 1976 (1968-1981) 2008 (2007-2008) 2009 (2009-2009) 2008 (2008-2008)
Scientific life 18 (11-27) 38 (34-38) 29 (28-31) 30 (28-32)
Quantitative data are expressed with median and 95% confidence interval.
NA= Not Applicable.
*Scopus Hirsch index calculated only for article published after 1994.
**ISI Hirsch index applicable for 320 authors. The applicability was 31/110 (28%) for 1945-1964, 72/120 (60%) for 1965-1979 and 217/244 (89%) for 1980-1999.
doi:10.1371/journal.pone.0012044.t001
Truth Survival
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available in Table S1. Therefore we planned an analysis using this
classification in the multivariate prognostic analysis.
Results
A total of 474 articles were included. The characteristics of
included first authors are given in Table 1 and of the articles
are given in Table 2, stratified by periods. There was a majority
of articles published by residents of the US and UK before
1980, and by residents of continental Europe after 1980. A
large majority of articles were published by male first authors,
who were not surgeons, with a median scientific life of 30 years.
The methodological quality, expressed according to scoring
systems or predictive value, was much better since 1980.
Table 2. Characteristics of included original articles.
Characteristics Publication year
1945-1964 1965-1979 1980-1999 Total
Total selected 110 120 244 474
Authorship
First author
Article with author publishing once 82 92 148 322
Articles with author publishing
several studies
28 28 96 152
First article
First article by author 94 105 181 380
Articles with repeated
same author
16 15 63 94
Article
Journal
Lancet 43 40 77 160
Gastroenterology 41 49 89 179
Other 26 31 78 135
Method
Non-randomized 80 60 80 220
Randomized trial 30 60 80 170
Meta-analysis 0 0 84 84
Quality
Score above median
yes 6 16 106 128
no 104 104 138 346
Positive predictive value
(Ioannidis)
$20% 7 20 136 311
,20% 103 100 108 474
Negative result
Y e s 1 9 3 55 71 1 1
No 91 85 187 363
Disease
Hepatitis 48 39 103 190
Portal hypertension 23 25 74 122
Other 39 56 67 162
Subject
Treatment 56 66 172 294
Diagnosis 14 18 31 63
Other 40 36 41 117
Specialty
Medicine 100 113 237 450
Surgery 10 7 7 24
doi:10.1371/journal.pone.0012044.t002
Truth Survival
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considered true, 90 were considered obsolete (19%) and 100 (21%)
false. The half-life of truth was 45 years. The survival rate of
conclusions was 85% (95%CI 83-89%) at 20 years and -52%
(95%CI, 47-57%) at 40 years.
The h-Index
The first author Scholar h-I (median; 95%CI) was 24 (20-27),
with a range from 1 to 85, and an increase of 0.87 (0.82-0.93) h-I
per year of scientific life. There was a skewed distribution, not
normal, with 33 articles published by 21 authors with h-I values -of
60 or higher. For authors publishing after 1994, the h-I, estimated
using Scopus, was 17 (15-20) with an increase of 1.13 (1.00-1.40)
per year. For the period after 1980, the h-I estimated using ISI,
was 21 (17-25) with an increase of 0.72 (0.63-0.88) per year. The
median baseline h-I was 0 (0-0) before 1965 and 6 (5-8) after 1980.
Factors associated with the h-I estimated using Google
scholar
As expected the h-I was highly associated with duration of
scientific life and recent publications (Table 3). Authors that had
published after 1980 had a significantly higher h-I (30; 26-33); for
those that had published earlier, the value was 23 (17-28) between
1965 and 1979, and 13 (9-15) between 1945 and 1964. There was
no association between gender and the h-I.
Articles with true conclusions had significantly higher h-I (28;
24-31) than those with obsolete (19; 15-25; P=0.002 vs. true) or
false conclusions (19; 16-25; P=0.01 vs. true) (Table 4). The same
trends were observed for the h-I ‘‘rate’’ per year 0.97 (95%CI
0.84-1.07) for true conclusions, vs. 0.76 for obsolete (95%CI 0.62-
0.86; P=0.07 vs. true) and 0.90 (95%CI 0.71-1.07; NS vs. true) for
false conclusions.
Using univariate and not time-dependent analysis, the h-I was
also associated with methodological quality either using scores
(Table 4) or positive predictive value categories (Figure 1),
randomization design, and with authors with several articles
included (Table 5).
There was no significant association between the h-I and truth
survival using time-dependent analysis both in uni- and multivar-
iate analyses (Table 5). Comparing the Scholar h-I there was no
significant difference between 50 years survival (main end point),
5065% (h-I above median) and 4664% (under the median),
respectively (P=0.63) (Figure 2). There was also no difference in
truth survival for Scopus h-I (Figure 3).
For the main endpoint the risk ratio of the h-I was 1.003 (0.994-
1.011) and was not significant (P=0.56). There was a significant
difference of the 50 years survival of conclusions according to the
negative or positive finding, 72612% (negative finding) and
4063% (positive finding), respectively (P,0.0001) (Figure 4).
In a subgroup analysis restricted to 111 articles with negative
conclusions we observed a significant independent predictive value
of the h-I in multivariate analysis (risk ratio=1.033; 95%CI,
1.008-1.059; P=0.009). Negative conclusions of authors with an
h-I .24 had an 82%66% 50 years survival vs. 65%69% for
those ,=24 (NS). The observed difference was even greater
among the Lancet’s studies: 74%616% vs. 47%618% (NS).
The 50 year survival of the 30 higher h-I ‘‘outstanding category’’
conclusions was 48% (95% CI 29-73%) vs. 35% (28-42%, P=0.10)
Table 3. Hirsch index according to characteristics of included first author.
Hirsch Index
median (95% CI) or Spearman’s rank coefficient; P value detailed if ,0.05
Characteristics h-Scholar Speed h-Scholar h-Scopus 1995-2009 Speed h-Scopus h-ISI 1980-2009 Speed h-ISI
n=474 n=474 n=227 n=227 n=217 n=217
All 24 (20-27) 0.87 (0.82-0.93) 17 (15-20) 1.21 (1.07-1.50) 21 (17-25) 0.73 (0.63-0.88)
Residence
US 28 (21-33) 0.94 (0.84-1.05) 17 (12-25) 1.31 (0.92-1.79) 25 (12-32) 0.97 (0.32-1.90)
UK 24 (16-31) 1.06 (0.80-1.36) 14 (3-22) 1.00 (0.33-1.64) 21 (12-28) 0.88 (0.57-1.16)
Italy 20 (20-29) 0.74 (0.45-1.03) 17 (15-21) 1.21 (1.07-1.50) 18 (17-26) 0.63 (0.39-0.63)
France 31 (20-40) 1.17 (0.83-1.6) 21 (16-31) 1.50 (1.14-2.21) 27 (18-46) 1.16 (0.89-1.51)
Europe (other) 20 (17-29) 0.70 (0.59-0.87) 11 (9-21) 0.79 (0.64-1.50) 19 (12-27) 0.63 (0.38-0.87)
Asia 24 (13-35) 1.08 (0.68-1.71) 20 (11-28) 1.43 (0.79-2.00) 29 (20-36) 1.11 (1.04-1.32)
Other 19 (17-24) 0.76 (0.54-0.89) 10 (3-15) 0.71 (0.21-1.07) 8 (0-16) 0.36 (0-0.73)
Gender
Male 25 (21-28) 0.88 (0.83-1.00) 17 (15-20) 1.04 (0.57-1.15) 23 (18-26) 0.71 (0.63-0.87)
Female 19 (16-25) 0.79 (0.62-1.29) 15 (8-16) 1.21 (1.07-1.46) 15 (7-20) 0.84 (0.30-0.92)
Scientific life
First publication date 0.01 (NS) 0.31 (,0.0001) -0.04 (NS) -0.04 (NS) -0.10 (NS) 0.33 (,0.0001)
Last publication date 0.44 (,0.0001) 0.14 (0.003) 0.54 (,0.0001) 0.50 (,0.0001) 0.23 (0.0006) 0.20 (0.003)
Scientific life (year) 0.43 (,0.0001) -0.27 (,0.0001) 0.26 (,0.0001) 0.25 (,0.0001) 0.13 (NS) -0.35 (,0.0001)
Authorship
First article by author 21 (18-25) 0.89 (0.81-1.00) 16 (13-19) 1.15 (1.00-1.36) 23 (18-25) 0.85 (0.70-0.92)
Articles with repeated
same author
31 (25-38)
(,0.0001)
0.85 (0.79-1.00) 15 (15-22) 1.07 (1.07-1.69) 18 (17-28) 0.63 (0.39-0.86)
doi:10.1371/journal.pone.0012044.t003
Truth Survival
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of the 30 higher vs others were 67% (44-90%) vs 60% (50-71%;
P=0.89) and 71% (51-90%) vs 59% (49-70%; P=0.73).
Concordance between the h-index estimated using
Google Scholar, Scopus, and ISI
Concordance between the h-I estimated using Google scholar
on the overall scientific life of authors and the h-I estimated using
Scopus and ISI for the scientific life after 1994, was assessed for the
217 authors of articles published after 1994 and applicable ISI (1a `
not applicable out of 227). There was a highly significant
concordance between the 3 h-I estimates. The Spearman’s rank
correlation between Scholar and Scopus was 0.72, between
Scholar and ISI 0.81 (P,0.0001) and between Scopus and ISI
0.82 (all P,0.0001). The median h-I Scholar value was 31
(95%CI, 28-36) with a median of 29 years (95%CI 28-32) of
scientific life; the median h-I Scopus value was 17 (95%CI, 15-21)
with a median of 15 years (95%CI, 15-15) of scientific life; the
median h-I ISI value was 21 (95%CI, 17-25). The rate of h-I per
year was 1.08 (95%CI, 0.96-1.13) according to Scholar 1.13
(95%CI, 1.00-1.40) according to Scopus and 0.73 (95%CI 0.63-
0.88). The classification of authors that ranked above/under the h-
I median by Scholar (.31), by Scopus (.17) or by ISI (.21) had a
high kappa concordance rate of = Scholar/Scopus 0.61
(SE=0.07; P,0.001), Scholar/ISI 0.69 (SE=0.07; P,0.001)
and Scopus/ISI 0.85 (SE=0.07; P,0.001). For h-I rate above/
below 1 per year, the kappa were Scholar/Scopus 0.45 (SE=0.06;
P,0.001), Scholar/ISI 0.59 (SE=0.06; P,0.001) and Scopus/ISI
Table 4. Hirsch index according to characteristics of included original articles.
Hirsch Index
median (95% CI) or Spearman’s rank coefficient; P value detailed if ,0.05
Characteristics h-Scholar Speed h-Scholar h-Scopus 1995-2009 Speed h-Scopus h-ISI 1980-2009 Speed h-ISI
Journal
Lancet 22 (19-27) 0.83 (0.76-0.89) 16 (12-22) 1.21 (0.93-1.64) 21 (17-29) 0.79 (0.58-0.92)
Gastroenterology 27 (22-30) 1.00 (0.87-1.15)0.02 21 (17-23) 1.50 (1.29-1.64) 26 (20-30) 1.01 (0.74-1.13)
Other 20 (20-29) 0.84 (0.76-1.00) 15 (15-17) 1.07 (1.07-1.21) 17 (17-20) 0.63 (0.39-0.63)
Method
Non-randomized 20 (17-24) 0.80 (0.71-0.94) 17 (15-21) 1.27 (1.07-1.50) 23 (18-27) 0.85 (0.64-1.09)
Randomized trial 30 (24-33) 0.0008 0.97 (0.87-1.07) 20 (13-25) 1.50 (1.00-1.86) 27 (17-31) 0.87 (0.60-1.00)
Meta-analysis 25 (20-38) 0.0003 0.85 (0.80-1.08) 15 (15-17) 1.07 (1.07-1.31) 17 (17-23) 0.63 (0.39-0.71)
Quality
Yes 36 (31-41),0.0001 1.08 (0.86-1.12) ,0.0001 22 (16-22)*0.01 1.69 (1.21-1.71) 0.006 26 (20-31) 0.89 (0.63-0.93)
No 20 (19-23) 0.81 (0.71-0.85) 15 (14-17) 1.07 (1.00-1.25) 18 (17-22) 0.63 (0.43-0.81)
Predictive value
$20% 33 (25-38),0.0001 1.08 (1.00-1.14) ,0.0001 16 (15-22) 1.07 (1.00-1.57) 20 (17-25) 0.70 (0.63-0.89)
,20% 20 (19-24) 0.83 (0.76-0.94) 15 (12-19) 1.00 (0.80-1.27) 22 (17-26) 0.77 (0.58-0.90)
Negative result
Yes 21 (18-29) 0.87 (0.81-1.00) 15 (12-17) 1.07 (0.92-1.31) 17 (13-23) 0.58 (0.41-0.85)
No 25 (20-28) 0.84 (0.74-1.00) 19 (16-21) 1.36 (1.14-1.57) 24 (18-27) 0.81 (0.63-0.91)
Disease
Hepatitis 27 (20-29) 0.97 (0.84-1.08) 21 (17-25) 1.50 (1.25-1.79) 27 (21-30) 1.00 (0.82-1.13)
Portal hypertension 25 (20-31) 0.88 (0.75-1.08) 16 (15-21) 1.11 (1.07-1.50) 17 (17-25) 0.03 0.63 (0.39-0.63)
0.0003
Other 22 (18-25) 0.83 (0.76-0.94) 12 (11-17) 0.004 0.93 (0.79-1.31) 0.004 14 (12-23) 0.0005 0.51 (0.32-
0.79),0.0001
Subject
Treatment 26 (20-31) 0.89 (0.84-1.00) 16 (15-21) 1.14 (1.07-1.50) 20 (17-25) 0.63 (0.62-0.87)
Diagnosis 26 (18-31) 0.97 (0.68-1.15) 17 (9-22) 1.21 (0.71-1.62) 26 (13-31) 0.83 (0.45-1.11)
Other 20 (14-25) 0.046 0.78 (0.68-0.97) 19 (15-22) 1.36 (1.15-1.64) 22 (16-27) 0.89 (0.53-1.13)
Specialty
Medicine 24 (20-28) 0.86 (0.81-0.97) 17 (15-21) 1.21 (1.07-1.50) 21 (17-25) 0.78 (0.63-0.89)
Surgery 23 (10-53) 1.05 (0.45-1.12) 15 (6-22) 1.07 (0.46-1.69) 17 (8-31) 0.39 (0.20-8.00)
Truth survival
True 28 (24-31) 0.002 0.97 (0.84-1.07) 0.01 17 (15-21) 1.21 (1.07-1.50) 22 (17-25) 0.71 (0.63-0.89)
Obsolete 19 (15-24) 0.76 (0.62-0.86) 15 (6-22) 1.08 (0.57-1.71) 18 (8-24) 0.63 (0.20-1.00)
False 19 (16-26) 0.90 (0.71-107) 19 (11-23) 1.36 (0.79-1.69) 26 (12-30) 0.88 (0.58-1.09)
doi:10.1371/journal.pone.0012044.t004
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Google Scholar, the h-I estimated using Scopus or ISI had similar
variability according to characteristics of included first author
(Table 3) and original articles (Table 4), and were also not
independently associated with truth survival (Table 5).
Predictive value of baseline Scholar h-index
For baseline H-I the prognostic value was opposite between uni
and multivariate analyses. Using univariate comparison (Table 5),
article with author baseline h-I greater than 3 (the median value) had
lower 50 year survival (18%) than article with lower baseline h-I
(42%; P,0.0001) and in multivariate analysis the quantitative value
was positively associated with survival (Risk ratio=0.027;
P=0.0001). This discrepancy was due to a very significant period
effect. After 1980 the 25 year survival of author with baseline h-I .3
was 66% (54-77%) versus 63% (50-76%; NS) in h-I#3, with in
multivariate analysis a significant positive prognostic value (risk
ratio=0.027; P=0.0001). Before 1980 the 25 year survival of author
with baseline h-I .3 was 19% (5-34%) versus 63% (50-76%; NS) in
h-I#3 (negative prognostic value), with in multivariate analysis a
significant positive prognostic value (risk ratio=1.052; P=0.04).
Discussion
We observed that the h-I at the end of the study was associated
with true conclusions, but its prognostic value did not survive with
time-dependent analysis as previously observed for methodological
quality. On the contrary baseline h-I (when the paper was written),
was significantly and independently associated with truth survival,
when adjusted on other covariables. Negative conclusions
remained a robust and independent predictor of truth survival [3].
Strength
We confirmed in the present study the intriguing prognostic
value of negative conclusions (72% vs. 40% for 50 years survival
for positive conclusions), which persisted after other factors had
been taken into account. This prognostic value was not due to
obsolete conclusions as among negative conclusions, as only 2% of
negative conclusions had been rated as obsolete compared to 25%
of positive conclusions. We found few negative studies which had
been published in order to reveal previous false positive
conclusions (Proteus phenomenon) [21]. An example is the article
which concluded that hepatitis B virus was not responsible for
primary biliary cirrhosis which was published 18 months after
another article had suggested this association [3]. There was no
significant difference in the h-I of authors with negative (h-I=21)
or positive (h-I=25) conclusions. If we accept that most published
research findings are false [4], the better survival of negative
findings (‘‘no relationships’’) is a corollary of this statement. This is
therefore the most plausible explanation of the better long term
survival of negative findings.
Subgroup analyses are hazardous, but in a multivariate analysis
restricted to 111 articles with negative conclusions we observed a
significant independent predictive value of the h-I. This retro-
spective observation without a priori hypothesis must be confirmed
by another study. We previously observed in the present cohort
that the prognostic value of negative versus positive conclusions
was mainly due to high differences among the randomized trials’
conclusions: 68613% for 52 negative conclusions compared with
1464% (P,0.001) for 118 positive conclusions [3]. One
hypothesis is that authors with an elevated h-I are principal
investigators of ‘‘better trials’’ with better findings survival than
those of authors with a lower h-I. From our analysis we cannot
conclude that this ‘‘author effect’’ is a cause or a consequence of
scientific performance. Some authors may be supported more by
industry for other reasons than their ‘‘intrinsic’’ quality. A means
of verifying whether ‘‘an intrinsic’’ author exists would have been
to assess the factors associated with survival among articles
published at the beginning of the authors’ scientific life.
Limitations
Our study has significant limitations. The study is retrospective
between 1945 and 2000 and only prospective for the last 10 years
of follow-up (updated in 2009). The inclusion criteria selected
authors who may not have been representative of the overall
biomedical community. They had published articles on liver
diseases with high methodological levels (majority of randomized
trials) in two competitive journals (mainly Lancet and Gastroen-
terology) with high impact factors in 2008, 28.4 and 12.6,
respectively. We also used methods to assess methodological
quality which are not the most recent and valid ones.
This selection should explain the high observed h-I (median of
24 for all periods and 30 for the period of 1980-1999). The h-I
cannot be compared between different scientific fields or between
different periods of publications [16,17]. However, the observed
median (h-I=30) is higher compared with h-I of the same medical
fields: versus other medical faculty members (same period): 7.6
mean h-I in 826 US oncologists [22], median 10 for 29 Dutch
professors in cardiology [23], and median 23 for 45 editorial board
members [24]. Because of this rather high h-I level, it is possible
Figure 1. Hirsch-index and positive predictive value of
research findings. On the vertical axis are plotted the Hirsch Index
estimated using Google Scholar. On the horizontal axis are plotted the
positive predictive value (PPV) of the conclusions of research findings,
classified in 9 categories according to Ioannidis [4]: 1) Adequately
powered randomized trial (RCT) with little bias and pre-study data
(median h-I=43); 2) Confirmatory meta-analysis of good quality RCTs
(h-I=22); 3) Meta-analysis of small inconclusive studies (h-I=41); 4)
Underpowered, but well-performed phase I/II RCT (h-I=37); 5)
Underpowered, poorly performed phase I/II RCT (h-I=22); 6) Adequate-
ly powered exploratory epidemiological study (h-I=20); 7) Underpow-
ered exploratory epidemiological study (h-I=25); 8) Discovery-oriented
exploratory research with massive testing (h-I=20); and 9) As 8, but
with more limited bias (h-I=17). Using Dunn’s multiple comparisons
test, the medians were significantly different between 1 and 5,7 and 9; 2
vs 9; 4 vs 5; 6 vs 7 and 9. Box plots were medians with 95% confidence
intervals and extremes values.
doi:10.1371/journal.pone.0012044.g001
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50 years truth survival percentage of studies without false or obsolete conclusion
Mean ± Standard error Logrank Significance (P) Risk ratio (expb) Significance (P)
h-Scholar 2010
.24 n=232 5065% 0.23 0.63 1.003 (0.994-1.011) 0.56
#24 n=240 4664%
h-Scholar baseline
.3 n=219 1865% 29.8 ,0.0001 1.027 (0.0131-0.041) 0.0001
#3 n=225 4265%
h-Top-scientist
.60 n=33 48611% 6 0.10 0.57 (0.30-1.08) 0.09
#60 n=441 3564%
h-Scopus*
.16 n=116 5368% 0.03 0.87 1.003 (0.984-1.022) 0.76
#16 n=111 4869%
h-ISI**
.21 n=107 5269% 1.99 0.16 0.999 (0.990-1.010 0.98
#21 n=110 45610%
Study conclusion
Negative n=111 72612% 20 ,0.0001 0.41 (0.26-0.63) 0.0001
Positive n=363 4063%
Quality
Methodological score
High n=128 6867% 0.1 0.71 1.08 (0.68-1.74) 0.71
Low n=346 4663%
Positive predictive value
$20% 5968% 0.2 0.65 0.87 (0.57-1.31) 0.50
,20% 3464%
Disease
Hepatitis n=190 5065%
Portal hypertension n=122 5366% 0.7 0.71 0.94 (0.65-1.33) 0.67
Other n=103 4165%
Type of research
Therapeutic n=294 5064%
Diagnostic n=63 1867% 2.2 0.02 1.39 (0.95-1.99) 0.09
Other n=117 4066%
Journal
Gastroenterology n=179 4865%
Lancet n=160 4365% 2.9 0.23 1.008 (0.75-1.36) 0.96
Other n=135 5366%
Specialty***
Medicine n=450 4763%
Surgery n=24 54611% 0.1 0.91 Not included
Methodology****
Meta-analysis n=84 8762%
Randomized trial n=170 9263%
Non-randomized n=220 8763% 1.0 0.33 Not included
*Analysis performed only for 244 articles published by authors still publishing after 1994.
**Analysis performed only for 217 articles published by authors still publishing after 1980 as there was too few authors with applicable h-ISI before 1980.
***Significance between h-ISI .17 and lower ***Not included in multivariate analysis as too small sample size for surgery articles.
****Survival analysis at 25 years because no meta-analysis was published before 1980. The squared correlation coefficient was 0.05 (P=0.0004) for truth survival.
doi:10.1371/journal.pone.0012044.t005
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significance of the h-I in multivariate analysis. ‘‘Top scientists’’ -
according to the h-I were at the borderline of the prognostic value
(Table 3). Enlarging the spectrum of authors could test this risk of
error.
There is no gold standard for scientific truth definition. We
used a definition that was decided by the majority vote of a
panel of 5 experts, 10 to 65 years after the findings’
publication. The main advantage was the duration of follow-
up with subsequent progresses in the field of knowledge. The
main weakness was the arbitrary choice of experts. To limit the
risk of bias, the experts were chosen from different domains of
Hepatology and had different ages [3]. We also adjusted the
prognosis analysis using the classification of studies according
to positive predictive values per Ioannidis [4]. The results were
similar to the previous adjustments using the -validated quality
scoring system of randomized trials and meta-analyses [3].
However we think that the positive predictive value estimates
could be improved for negative findings and for diagnostic
studies, which is a growing part of clinical research.
The h-I estimates had limitations and we cannot rule out that
these limitations might be able to explain the absence of clear
and independent prognostic values [7–10,16–17, 25]. The first
limitation is the reliability of a citation index in oldest years
(1945-1980) before the prospective existence of PubMed and
Google Scholar. The second main limitation is the commonness
of last names which could introduce false estimates of the h-I.
However, with the high risk names we used ‘‘liver’’ as a
supplementary selection criterion in Scholar research and
checked the authorship twice using Scopus for authors still
publishing after 1994. Moreover, the main results were similar
using two other estimates, Scopus and ISI (Table S2), which
were significantly concordant.
Finally the extrapolation of baseline h-I at the year when the
paper was written suggest a clear and independent prognostic
value of h-I. The main limitation of this index in comparison with
the 2010 h-I estimates, is its indirect assessment. This extrapola-
tion rely on the normality and linearity of the h-I progression rate.
We used median to reduce the risk of variability but a real
prospective validation of the h-I prognostic value is needed.
Conclusion
The h-I is simple, probably more accurate than other citation
indexes for estimating authors’ scientific outputs, and it is accepted
when its limitations are understood [25], with [26] or without
[7,10] irony. We agree with Horne et al, that retaining a dignified
aloofness to the h-I could be difficult for those with scores of less
than 30 [7].
For living hepatologists, at least, our conclusions were
balanced. The present study failed to clearly demonstrate that
the h-index of authors was a prognostic factor for truth survival.
However the h-I was partly validated as associated with true
conclusions, the methodological quality of trials and with positive
predictive values combining power, ratio of true to not-true
relationships and bias.
Furthermore an indirect (extrapolated) estimate of baseline h-I
clearly observed a high and independent prognostic value for
articles published after 1980. Prospective study in the next decades
should be initiated to confirm this observation.
Figure 2. Survival of truth according to the Scholar Hirsch-
index. Survival of 474 conclusions according to the h-index above the
median value=24, or not, using the Google Scholar data-base from
1945 to 2009. There was no significant difference between 50 years
survival, 5065% (black line) and 4664% (grey line), respectively
(P=0.63).
doi:10.1371/journal.pone.0012044.g002
Figure 3. Survival of truth according to the Scopus Hirsch-
index. Survival of 227 conclusions according to the h-index above of
the median value=16, using the Scopus data-base from 1995 to 2009.
There was no significant difference between 50 years survival, 5368%
(black line) and 4869% (grey line), respectively (P=0.63).
doi:10.1371/journal.pone.0012044.g003
Figure 4. Survival of 474 conclusions according to the negative
or positive finding. There was a significant difference between 50
years survival, 72612% (black line) and 4063% (grey line), respectively
(P,0.0001).
doi:10.1371/journal.pone.0012044.g004
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